바실루스 코아굴란스 관련 과민성 대장 증후군(IBS)
B 근거 적어도 하나의 무작위 시험이 이를 지지하며, 대체로 일관된 결과를 보입니다.IBS의 복통, 팽만감, 설사를 줄입니다. 아포형성 특성으로 우수한 안정성과 위산 생존율을 제공합니다.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dbacillus\u002Dcoagulans\u0026condition\u003Dibs';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
결론
IBS의 복통, 팽만감, 설사를 줄입니다. 아포형성 특성으로 우수한 안정성과 위산 생존율을 제공합니다.
Key Study Findings
Meta-Analysis
Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome.
Dose: None
vs: placebo
Outcome: improvement in key IBS symptoms
효과: None
None
대상 집단: patients with IBS from 32 RCTs evaluating 10 probiotic strains
Randomized Controlled Trial
n=61
4 weeks
Double-blind
Effects of a Bacillus subtilis HU58 and Heyndrickxia faecalis SC208 spore-forming probiotic formula on gastrointestinal …
Dose: None
vs: Placebo
Outcome: Abdominal pain (NRS) and stool consistency (BSFS)
효과: None
P = 0.003 (pain); P = 0.035 (s
대상 집단: Adults with diarrhoea-predominant IBS (IBS-D)
Randomized Controlled Trial
n=100
12 weeks
Role of Bacillus coagulans (Heyndrickxia coagulans)BCP92 in managing irritable bowel syndrome: A randomized, double-blind, multicenter, …
Dose: None
vs: Control
Outcome: Pain outcomes
효과: None
P < .001
대상 집단: IBS patients
Meta-Analysis
Outcome-Specific Efficacy of Different Probiotic Strains and Mixtures in Irritable Bowel Syndrome: A Systematic Review …
Dose: Various probiotic strains/mixtures
vs: Placebo
Outcome: Outcome-specific efficacy ranking in IBS
효과: None
None
대상 집단: Adults with IBS (RCTs)
Randomized Controlled Trial
12 weeks
Double-blind
The Efficacy and Safety of Single-Strain Probiotic Formulations Containing Bifidobacterium lactis or Bacillus coagulans in …
Dose: 20.5%
vs: placebo
Outcome: IBS symptom improvement
효과: None
p = 0.038
대상 집단: Adults with IBS
Review
Oral microbial shift induced by probiotic Bacillus coagualans along with its clinical perspectives.
Dose: None
vs: None
Outcome: colitis/IBD severity
효과: None
None
대상 집단: None
Key Statistics
3
연구
400
참여자
↑
Positive
B
등급
Referenced Papers
Journal of clinical …
2026
Beneficial microbes
2026
Medicine
2024
6 인용
Nutrients
2023
33 인용
Oral microbial shift induced by probiotic Bacillus coagualans along with its clinical perspectives.
Review
Journal of oral …
2023
12 인용
International journal of …
2023
9 인용
Journal of clinical …
2023
9 인용
Medicine
2021
45 인용
Journal of dietary …
2021
33 인용
European journal of …
2020
20 인용
Scientific reports
2019
65 인용
Beneficial microbes
2019
45 인용
Beneficial microbes
2019
29 인용
Food & nutrition …
2018
162 인용
Beneficial microbes
2018
59 인용
Nutrition journal
2016
102 인용
European review for …
2014
33 인용
Gastroenterology and hepatology …
2014
Postgraduate medicine
2009
144 인용
Methods and findings …
2009
104 인용
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- general:
- 1-2 billion CFU/day
- ibssupport:
- 2 billion CFU/day (GBI-30 6086 strain)
상한량: Well-tolerated up to 6 billion CFU/day in clinical trials
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| None | -- | Positive | -- |
| None | 4 weeks | Positive | 61 |
| None | 12 weeks | Positive | 100 |
| Various probiotic strains/mixtures | -- | Positive | -- |
| 20.5% | 12 weeks | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
권장 복용 시간: With meals for optimal spore germination and colonization
Safety & Side Effects
보고된 부작용
- ⚠ Mild gas during initial use (generally less than other probiotics due to spore form)
- ⚠ Occasional bloating
- ⚠ Rare loose stools
알려진 상호작용
- ● Antibiotics (spore form is more resistant than vegetative probiotics, but spacing still recommended)
- ● Immunosuppressants (theoretical risk in immunocompromised patients)
일일 최대 섭취 허용량: Well-tolerated up to 6 billion CFU/day in clinical trials
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does 바실루스 코아굴란스 help with 과민성 대장 증후군(IBS)?
Based on 3 studies with 400 participants, there is moderate evidence from clinical studies that 바실루스 코아굴란스 may support 과민성 대장 증후군(IBS) management. Our evidence grade is B (Good Evidence).
How much 바실루스 코아굴란스 should I take for 과민성 대장 증후군(IBS)?
Studies have used various dosages. A commonly studied range is 1-2 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of 바실루스 코아굴란스?
Reported side effects may include Mild gas during initial use (generally less than other probiotics due to spore form), Occasional bloating, Rare loose stools. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for 바실루스 코아굴란스 and 과민성 대장 증후군(IBS)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 3 peer-reviewed studies with 400 total participants. The overall direction of effect is positive.
Related Evidence
관련 다른 성분: 과민성 대장 증후군(IBS)
References
- [1] Roman Maslennikov et al.. J Clin Med. 2026. Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome. doi:10.3390/jcm15031152 PubMed
- [2] K Sorensen et al.. Benef Microbes. 2026. Effects of a Bacillus subtilis HU58 and Heyndrickxia faecalis SC208 spore-forming probiotic formula on gastrointestinal health: results of a randomised, … doi:10.1163/18762891-bja00113 PubMed
- [3] Sohel S Shaikh et al.. Medicine (Baltimore). 2024. Role of Bacillus coagulans (Heyndrickxia coagulans)BCP92 in managing irritable bowel syndrome: A randomized, double-blind, multicenter, placebo-controlled clinical trial. doi:10.1097/MD.0000000000039134 PubMed
- [4] Peiwei Xie et al.. Nutrients. 2023. Outcome-Specific Efficacy of Different Probiotic Strains and Mixtures in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis. doi:10.3390/nu15173856 PubMed
- [5] Aysha Jebin A et al.. J Oral Biol Craniofac Res. 2023. Oral microbial shift induced by probiotic Bacillus coagualans along with its clinical perspectives. doi:10.1016/j.jobcr.2023.03.013 PubMed
- [6] Ludovic D Langlois et al.. Int J Mol Sci. 2023. Effects of Glutamine, Curcumin and Fish Bioactive Peptides Alone or in Combination on Intestinal Permeability in a Chronic-Restraint Stress Model. doi:10.3390/ijms24087220 PubMed
- [7] Barbara Skrzydło-Radomańska et al.. J Clin Med. 2023. The Efficacy and Safety of Single-Strain Probiotic Formulations Containing Bifidobacterium lactis or Bacillus coagulans in Adult Patients with Irritable Bowel … doi:10.3390/jcm12144838 PubMed
- [8] Anil Kumar Gupta et al.. Medicine (Baltimore). 2021. Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A prospective, interventional, randomized, double-blind, placebo-controlled clinical study [CONSORT … doi:10.1097/MD.0000000000023641 PubMed
- [9] Chiranjit Maity et al.. J Diet Suppl. 2021. Impact of a Gastrointestinal Stable Probiotic Supplement Bacillus coagulans LBSC on Human Gut Microbiome Modulation. doi:10.1080/19390211.2020.1814931 PubMed
- [10] Khadijeh Abhari et al.. Eur J Nutr. 2020. Is Bacillus coagulans supplementation plus low FODMAP diet superior to low FODMAP diet in irritable bowel syndrome management? doi:10.1007/s00394-019-02060-y PubMed
- [11] Ratna Sudha Madempudi et al.. Sci Rep. 2019. Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel … doi:10.1038/s41598-019-48554-x PubMed
- [12] Y Mu et al.. Benef Microbes. 2019. Bacillus coagulans and its applications in medicine. doi:10.3920/BM2019.0016 PubMed
- [13] Y Mu et al.. Benef Microbes. 2019. Bacillus coagulans and its applications in medicine. doi:10.3920/BM2018.0016 PubMed
- [14] Muhammed Majeed et al.. Food Nutr Res. 2018. Bacillus coagulans MTCC 5856 for the management of major depression with irritable bowel syndrome: a randomised, double-blind, placebo controlled, multi-centre, … doi:10.29219/fnr.v62.1218 PubMed
- [15] M Ratna Sudha et al.. Benef Microbes. 2018. Efficacy of Bacillus coagulans Unique IS2 in treatment of irritable bowel syndrome in children: a double blind, randomised placebo controlled … doi:10.3920/BM2017.0129 PubMed
- [16] Muhammed Majeed et al.. Nutr J. 2016. Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled … doi:10.1186/s12937-016-0140-6 PubMed
- [17] R Urgesi et al.. Eur Rev Med Pharmacol Sci. 2014. A randomized double-blind placebo-controlled clinical trial on efficacy and safety of association of simethicone and Bacillus coagulans (Colinox®) in patients … PubMed
- [18] Mehran Rogha et al.. Gastroenterol Hepatol Bed Bench. 2014. The efficacy of a synbiotic containing Bacillus Coagulans in treatment of irritable bowel syndrome: a randomized placebo-controlled trial. PubMed
- [19] Larysa Hun. Postgrad Med. 2009. Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. doi:10.3810/pgm.2009.03.1984 PubMed
- [20] B J Dolin. Methods Find Exp Clin Pharmacol. 2009. Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome. doi:10.1358/mf.2009.31.10.1441078 PubMed
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.